Skip to main contentAI and Advanced
/
MOREPENLAB · NSEMarket ticker unavailable · configure an authorised index feed
MO
NSE · Equity shares · Biotechnology & Drugs-8.82 · -7.62%
Morepen Laboratories MOREPENLAB
NSE:INR 106.9
BSE:INR 79.48
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
Temporary source issue: live-price. Available sections remain usable while the affected layer retries on a later request.
AI analysis and Advanced tools for MOREPENLAB
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 115.72
Day rangeINR 104.8 — INR 116.68
52-week rangeINR 33.05 — INR 122.55
Volume1.86 Cr
Market cap4,355.14
P/E23.09
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)1,805.69
Net Income (INR Cr)94.88
Rev Growth (5 Year %)8.73
EPS Growth (5 Year %)-4.27
P/E Ratio23.09
EPS1.35
Research path: Interpret Morepen Laboratories's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
MOREPENLABMorepen Laboratories1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 1,936.12 | 1,778.1 | 1,293.21 |
| Other Liabilities Total | 44.41 | 44.27 | 38.32 |
| Long Term Debt | 133.6 | 25.76 | 3.36 |
| Common Stock Total | 109.58 | 109.58 | 102.23 |
| Other Current Assets Total | 488.16 | 30.91 | 43.2 |
| Total Assets | 1,936.12 | 1,778.1 | 1,293.21 |
| Current Portof LT Debt/Capital Leases | 69.99 | 19.82 | 2.14 |
| Cash | 31.19 | 27.38 | 16.95 |
| Total Equity | 1,246.44 | 1,156.23 | 847.23 |
| Long Term Investments | 108.84 | 14.94 | 8.44 |
| Retained Earnings(Accumulated Deficit) | 1,136.85 | 501.88 | 383.86 |
| Total Common Shares Outstanding | 54.8 | 54.8 | 51.12 |
| Tangible Book Valueper Share Common Eq | 20.58 | 18.43 | 14.73 |
| Total Liabilities | 689.68 | 621.87 | 445.98 |
| Total Debt | 207.86 | 105.1 | 29 |
| Short Term Investments | 38.85 | 77.81 | Not available |
| Cashand Short Term Investments | 70.04 | 105.19 | 16.95 |
| Total Receivables Net | 333.59 | 396.76 | 356.08 |
| Deferred Income Tax | 16.46 | 6.98 | 2.25 |
| Accounts Receivable-Trade Net | 333.14 | 325.93 | 326.49 |
| Property/Plant/Equipment Total-Net | 415.59 | 370.33 | 237.66 |
| Minority Interest | 0.65 | 30.73 | 0 |
| Total Current Liabilities | 490.3 | 500.65 | 402.04 |
| Total Inventory | 271.83 | 557.32 | 462.73 |
| Accounts Payable | 317.24 | 363.3 | 295.03 |
| Other Currentliabilities Total | 103.07 | 43.79 | 52.56 |
| Total Long Term Debt | 137.86 | 39.24 | 3.36 |
| Intangibles Net | 118.96 | 72.04 | 19.67 |
| Other Long Term Assets Total | 129.03 | 0.23 | 0.24 |
| Note Receivable-Long Term | 0.08 | 86.7 | 63.68 |
| Total Current Assets | 1,163.61 | 1,159.37 | 889.04 |
| Capital Lease Obligations | 4.26 | 13.48 | Not available |
| Accumulated Depreciation Total | Not available | -275.78 | -261.4 |
| Accrued Expenses | Not available | 27.71 | 28.82 |
| Other Equity Total | Not available | -8.4 | -8.65 |
| Prepaid Expenses | Not available | 69.18 | 10.09 |
| Additional Paid-In Capital | Not available | 553.16 | 369.79 |
| Property/Plant/Equipment Total-Gross | Not available | 646.11 | 499.06 |
| Goodwill Net | Not available | 74.47 | 74.47 |
| Notes Payable/Short Term Debt | Not available | 46.04 | 23.49 |
Fundamentals
Valuation and ratios
Valuation
PEG Ratio0.97
Price to Sale Ratio2.41
Growth
Debt 5Yr CAGR %8.74
Margins
Operating Margin 12m8.92
Operating Margin 5y Avg6.6
Net Profit Margin 12m7.21
Net Profit Margin 5y5.45
Yield
Dividend Yield %0.26
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskHigh risk
Board Risk60.59
Analyst consensus
Analyst consensus unavailable.
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,944 | 4.66 L | 38.4 | — |
| Divi's Laboratories | INR 8,291.55 | 2.20 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,965 | 1.89 L | 72.73 | — |
| Cipla | INR 1,475 | 1.19 L | 27.57 | — |
| Zydus Lifesciences | INR 1,106.25 | 1.10 L | 21.19 | — |
Shareholding
Ownership
- Promoter
- 35.65%
- FII
- 1.46%
- MF
- 0.05%
- Other
- 62.89%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Morepen Laboratories Establishes Wholly Owned Subsidiary in Dubai - UPPERNEWSMarket news · 7 Jul 2026, 7:34 pm
Morepen Laboratories Establishes Wholly Owned Subsidiary in Dubai UPPERNEWS
Morepen Begins Commercial Supplies Under ₹825 Crore CDMO Contract - Machine MakerMarket news · 7 Jul 2026, 2:36 pm
Morepen Begins Commercial Supplies Under ₹825 Crore CDMO Contract Machine Maker
Morepen Laboratories accepts resignation of GM Bhola Prasad - scanx.tradeMarket news · 6 Jul 2026, 9:54 pm
Morepen Laboratories accepts resignation of GM Bhola Prasad scanx.trade
Kirloskar Pneumatic Company Ltd leads losers in 'A' group - Business StandardMarket news · 2 Jul 2026, 3:04 pm
Kirloskar Pneumatic Company Ltd leads losers in 'A' group Business Standard
Morepen Laboratories appoints Sanjay Suri as Managing Director - Indian Pharma PostMarket news · 2 Jul 2026, 6:58 am
Morepen Laboratories appoints Sanjay Suri as Managing Director Indian Pharma Post
Morepen updates on ₹825 crore CDMO mandate; completes first commercial batch - BusinessLineMarket news · 1 Jul 2026, 4:12 pm
Morepen updates on ₹825 crore CDMO mandate; completes first commercial batch BusinessLine
Corporate actions
Events
- annual General MeetingAGM
- board MeetingsQuarterly Results
- dividendRs.0.2000 per share(10%)Final Dividend
- board Meetings(Revised)
- board MeetingsAudited Results
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- annual General MeetingAGM
Rusaka Markets Community
Discussion and sentiment for Morepen Laboratories
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Morepen Laboratories Limited is a pharmaceutical company. The Company is in the business of manufacturing, producing, developing and marketing a range of active pharmaceutical ingredients (APIs), branded and generic formulations and also home health products. Its APIs include Apixaban, Edoxaban, Linagliptin, Linagliptin + Metformin, Empagliflozin, Empagliflozin + Metformin, Atorvastatin, Rosuvastain, Rivaroxaban, Fexofenadine, Montelukast (Oral), Montelukast (Chewable), Montelukast Sodium, among others. Its finished formulations include Intebact Capsules, Intelicaps Lax, Rythmix Kid Drop, Rythmix Kid Syrup, Kompact Powder, Saltum and Acifix 3X Suspension among others. Its home health products include Dr. Morepen Nebulizer Model CN-11, Dr. Morepen Pulse Oximeter Model PO-12A, Dr. Morepen Breathe Free Vaporizer Model VP-06 and Dr. Morepen Pulse Oximeter Model PO-12A, among others. Its subsidiaries include Dr. Morepen Limited, Morepen Devices Limited, and Total Care Limited.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- MOREPENLAB
- BSE Code
- 500288
Questions
Stock FAQ
What is the symbol and ISIN of Morepen Laboratories?
Morepen Laboratories has the symbol MOREPENLAB and ISIN - INE083A01026.
What is the current price of Morepen Laboratories?
Morepen Laboratories is currently trading at INR 106.90.
What are the year high and year low of Morepen Laboratories?
Morepen Laboratories has a year high of INR 122.55 and a year low of INR 33.05.
What is the market capitalization of Morepen Laboratories?
Morepen Laboratories has a market capitalization of INR 4,355.14 crore.
What is the P/E ratio of Morepen Laboratories?
Morepen Laboratories has a P/E ratio of 23.09.
What is the dividend yield of Morepen Laboratories?
Morepen Laboratories has a dividend yield of 0.26%.
How is the financial performance of Morepen Laboratories based on revenue, net income, and EPS?
Morepen Laboratories has revenue of INR 1,805.69 crore, net income of INR 94.88 crore, and EPS of INR 2.13.
What is the book value of Morepen Laboratories?
Morepen Laboratories has a book value of NA.
What is the debt-to-equity ratio of Morepen Laboratories?
Morepen Laboratories has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Morepen Laboratories?
Morepen Laboratories has a price-to-book ratio of NA and a price-to-sales ratio of 2.41.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.